These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19960343)

  • 61. Role of XRCC1 gene polymorphisms in non-small cell lung cancer cisplatin-based chemotherapy, and their effect on clinical and pathological characteristics.
    Liu HF; Liu JS; Deng JH; Wu RR
    Genet Mol Res; 2016 Dec; 15(4):. PubMed ID: 28081275
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease.
    Choi MK; Hong JY; Chang W; Kim M; Kim S; Jung HA; Lee SJ; Park S; Chung MP; Sun JM; Park K; Ahn MJ; Ahn JS
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1217-25. PubMed ID: 24696125
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.
    de las Peñas R; Sanchez-Ronco M; Alberola V; Taron M; Camps C; Garcia-Carbonero R; Massuti B; Queralt C; Botia M; Garcia-Gomez R; Isla D; Cobo M; Santarpia M; Cecere F; Mendez P; Sanchez JJ; Rosell R;
    Ann Oncol; 2006 Apr; 17(4):668-75. PubMed ID: 16407418
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Predictive value of STMN1 gene promoter polymorphism (-2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine.
    Mlak R; Krawczyk P; Ciesielka M; Homa I; Powrózek T; Prendecka M; Kozioł P; Milanowski J; Małecka-Massalska T
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):621-9. PubMed ID: 26220844
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
    Tas F; Demir C; Camlica H; Ustuner Z; Topuz E
    Med Oncol; 2004; 21(3):233-40. PubMed ID: 15456950
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival.
    Liu L; Wu C; Wang Y; Zhong R; Duan S; Wei S; Lin S; Zhang X; Tan W; Yu D; Nie S; Miao X; Lin D
    J Thorac Oncol; 2011 Nov; 6(11):1793-800. PubMed ID: 21841506
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
    Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
    Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
    Rocha Lima CM; Rizvi NA; Zhang C; Herndon JE; Crawford J; Govindan R; King GW; Green MR;
    Ann Oncol; 2004 Mar; 15(3):410-8. PubMed ID: 14998842
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
    Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
    Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy.
    Fujita S; Masago K; Hatachi Y; Fukuhara A; Hata A; Kaji R; Kim YH; Mio T; Mishima M; Katakami N
    BMC Med Genet; 2010 Nov; 11():167. PubMed ID: 21114867
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Role of the RAD51 G172T polymorphism in the clinical outcome of cervical cancer patients under concomitant chemoradiotherapy.
    Nogueira A; Catarino R; Faustino I; Nogueira-Silva C; Figueiredo T; Lombo L; Hilário-Silva I; Pereira D; Medeiros R
    Gene; 2012 Aug; 504(2):279-83. PubMed ID: 22634097
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
    Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
    Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
    [TBL] [Abstract][Full Text] [Related]  

  • 75. RAD51 G135C gene polymorphism and risk of colorectal cancer in Kashmir.
    Nissar S; Baba SM; Akhtar T; Rasool R; Shah ZA; Sameer AS
    Eur J Cancer Prev; 2014 Jul; 23(4):264-8. PubMed ID: 24871558
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].
    Xu C; Wang X; Zhang Y; Li L
    Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):912-7. PubMed ID: 22152690
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
    Ludovini V; Floriani I; Pistola L; Minotti V; Meacci M; Chiari R; Garavaglia D; Tofanetti FR; Flacco A; Siggillino A; Baldelli E; Tonato M; Crinò L
    J Thorac Oncol; 2011 Dec; 6(12):2018-26. PubMed ID: 22052224
    [TBL] [Abstract][Full Text] [Related]  

  • 78. RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.
    Dong S; Guo AL; Chen ZH; Wang Z; Zhang XC; Huang Y; Xie Z; Yan HH; Cheng H; Wu YL
    J Hematol Oncol; 2010 Mar; 3():10. PubMed ID: 20226083
    [TBL] [Abstract][Full Text] [Related]  

  • 79. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
    Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer.
    Alberola V; Sarries C; Rosell R; Taron M; de las Peñas R; Camps C; Massuti B; Insa A; Garcia-Gomez R; Isla D; Artal A; Muñoz MA; Cobo M; Bover I; Gonzalez-Larria JL; Terrasa J; Almenar D; Barcelo R; Diz P; Sanchez-Ronco M; Sanchez JJ
    Clin Lung Cancer; 2004 May; 5(6):360-5. PubMed ID: 15217535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.